ProfileGDS5678 / 1433262_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 53% 53% 52% 54% 60% 54% 56% 52% 53% 53% 52% 53% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3612453
GSM967853U87-EV human glioblastoma xenograft - Control 23.3091153
GSM967854U87-EV human glioblastoma xenograft - Control 33.3007953
GSM967855U87-EV human glioblastoma xenograft - Control 43.214352
GSM967856U87-EV human glioblastoma xenograft - Control 53.2869454
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6714560
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4178654
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4107456
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2590452
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2866153
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2946353
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2407952
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3110953
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3021753